Clinical Trial Update: Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating a combination of selinexor, daratumumab, carfilzomib, and dexamethasone for high-risk, recurrent…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DARZALEX (daratumumab)
• Dexamethasone (Decadron) (dexamethasone)
• Kyprolis (carfilzomib)
• XPOVIO (selinexor) (selinexor)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING